Kaken Pharmaceutical: 2024 Annual General Meeting of Shareholders Convocation Notice and Shareholders' Meeting Materials
Kaken Pharmaceutical: Independent Officer Notification Form
Kaken Pharmaceutical: Corporate Governance Report 2024/05/30
Kaken Pharmaceutical: Transfer of intellectual property of “NM26” and conclusion of a sales partnership option agreement
Kaken Pharmaceutical: [Delay] Announcement of measures to realize management that is conscious of capital costs and stock prices
Kaken Pharmaceutical: Construction of a manufacturing plant for fermented pesticide raw materials at the Shizuoka Plant
Kaken Pharmaceutical: Measures aimed at realizing management that is conscious of capital costs and stock prices
Kaken Pharmaceutical: [Overview] Consolidated financial results for the fiscal year ended 2024/3/31 [JGAAP]
Kaken Pharmaceutical: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Kaken Pharmaceutical: Succession of manufacturing and sales approval for 2 products from Eisai
Scientific Research Pharmaceutical: Change Report
Kaken Pharmaceutical: [Delayed][Summary]Consolidated Financial Results for the Third Quarter of Fiscal 2023 (Nine-Month Period Ended December 31, 2023) [JGAAP]
Scientific Research Pharmaceutical: Confirmation Letter
Scientific Research & Pharmaceutical: Quarterly Report - 104th Term 3rd Quarter (2023/10/01 - 2023/12/31)
Kaken Pharmaceutical: Summary of Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Kaken Pharmaceutical: Report on Corporate Governance 2023/12/22
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
Kaken Pharmaceutical: [Delayed][Summary]Consolidated Financial Results for the Second Quarter of Fiscal 2023 (Six-Month Period Ended September 30, 2023) [JGAAP]
Kaken Pharmaceutical: Confirmation letter
Kaken Pharmaceutical: Quarterly Report - 104th Second Quarter (2023/07/01 - 2023/09/30)
No Data